No Data
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $25
Cathie Wood Reshuffles Portfolio Ahead of Q2, Buys SpaceX, Eli Lilly, Meta; Pares AMD, Roku
Adaptive Biotechnologies Shares Are Trading Higher After Morgan Stanley Raised Its Price Target on the Stock From $18 to $20.
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20
Adaptive Biotechnologies(ADPT.US) Officer Sells US$8.5 Million in Common Stock
$Adaptive Biotechnologies(ADPT.US)$ Officer ROBINS HARLAN S sold 386.24K shares of common stock on Jul 2, 2026 at an average price of $22.01 for a total value of $8.5 million.Source: Announcement
Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing